Commit Biologics, a company focused on treating cancer and autoimmune diseases by activating the complement system, has secured €5.5 million in additional seed funding. This new investment brings its total seed financing to €21.5 million. The round was led by
Lutris Pharma, a clinical-stage biopharmaceutical company, has raised $30 million in a financing round to advance the development of LUT014, an innovative topically applied gel designed to reduce the acneiform rashes caused by EGFRi therapies, a common side effect of
Orgenesis, a global biotech company has secured a $5 million equity line of credit from Williamsburg Venture Holdings. The deal provides $750,000 upon registration effectiveness, with a further $4.25 million accessible over two years. The funding will support Orgenesis’ initiatives
Lyndra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering long-acting oral therapies, has announced the appointment of Adam Sayer as its new President and Chief Executive Officer. Sayer, who also joins the company’s Board of Directors, succeeds Jessica Ballinger, the
Argonaut Manufacturing Services and Akoya Biosciences have announced a strengthened partnership, with Argonaut taking on the role of manufacturing partner for Akoya’s in vitro diagnostic (IVD) assays currently under development. This collaboration builds upon years of successful teamwork and highlights
Elevaris Medical Devices was established following the integration of Spectra Medical and XL Precision Technologies, two well-regarded Contract Development and Manufacturing Organisations (CDMOs) within the medical device sector. The merger, announced in September 2024, combines the complementary strengths of both
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO), has announced the completion of a new sterile manufacturing facility in Nottingham, UK. This addition complements the company’s existing 50,000 sq. ft. Trent Gateway site and is specifically designed
miRecule, a biotechnology company developing RNA-based therapies, has announced a new strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to accelerate the development and clinical supply of its innovative Antibody-RNA Conjugate (ARC) therapies. The collaboration aims to
miRecule, a biotechnology company developing RNA-based therapies, has announced a new strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to accelerate the development and clinical supply of its innovative Antibody-RNA Conjugate (ARC) therapies. The collaboration aims
Kenox Pharmaceuticals Inc. has expanded its drug development services by introducing small-scale non-sterile GMP capabilities to support GLP preclinical studies. The company, focused on Orally Inhaled and Nasal Drug Products (OINDPs), aims to accelerate drug development by providing a streamlined
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
